tradingkey.logo

Lilly's Jaypirca Met Primary Endpoint In Head-To-Head Phase 3 Study Versus Imbruvica

ReutersDec 7, 2025 9:36 PM

- Eli Lilly and Co LLY.N:

  • LILLY'S JAYPIRCA (PIRTOBRUTINIB) MET ITS PRIMARY ENDPOINT IN FIRST-OF-ITS-KIND, HEAD-TO-HEAD PHASE 3 STUDY VERSUS IMBRUVICA (IBRUTINIB)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI